Tirzepatide activates both GLP-1 and GIP receptors, targeting appetite and metabolic rate through two pathways instead of one. Dynamis providers determine which protocol fits your body.
If single-receptor GLP-1 medications haven’t delivered the results you expected, the issue may be that one hormonal pathway isn’t enough to overcome your body’s resistance.
BEST FOR
Maximum appetite and metabolic support
METHOD
Weekly subcutaneous injection
FREQUENCY
Once weekly with scheduled reviews
Tirzepatide clinical trials showed participants losing 16.5% to 22.4% of their body weight over 72 weeks. Nearly 75% of participants achieved at least 15% body weight reduction in the first 16 weeks. These aren’t temporary drops, they reflect sustained changes in appetite, food intake, and energy balance.
The GLP-1 pathway slows gastric emptying and increases satiety signals to your brain. You feel fuller longer on smaller portions, and cravings that previously felt overwhelming become manageable. This makes adherence to healthier eating patterns sustainable rather than forced.
GIP co-activation enhances insulin response and drives changes in energy expenditure beyond what GLP-1 alone can achieve. The synergistic effect means your body is working with you, not against you, as you build healthier habits.
Weight loss with tirzepatide often comes with improvements in blood sugar control, insulin sensitivity, and cardiovascular risk factors. Many participants see favorable changes in lipid profiles and blood pressure independent of weight reduction alone.
Tirzepatide is a synthetic peptide that activates two hormone receptors: GLP-1 and GIP. The FDA approved it as Mounjaro for type 2 diabetes (2022) and as Zepbound for chronic weight management (2023).
The dual mechanism produces a stronger insulin and appetite response than either pathway alone. This translates to greater appetite suppression and more robust metabolic benefits than single-receptor medications.
We review your medical history and current medications, then order baseline labs to assess kidney function, liver health, and metabolic markers before starting treatment.
Your board-certified provider reviews your labs and goals to determine your starting dose and titration schedule. Your personalized protocol reflects your medical history and response potential.
You self-administer a weekly subcutaneous injection. Within days, dual GLP-1/GIP activation reduces appetite, slows gastric emptying, and enhances metabolic function.
You check in with your provider every 2-4 weeks initially. Your Personal Health Coach tracks progress and works with your provider to adjust dosing based on results and tolerance.
Both are GLP-1 receptor agonists, but tirzepatide adds GIP receptor activation. This dual-pathway approach produced greater weight loss than semaglutide in head-to-head clinical trials. Your provider can discuss which medication fits your specific metabolic profile and goals.
Most participants report reduced appetite within the first 1-2 weeks. Measurable weight loss typically begins in weeks 3-4, with significant changes accumulating over 8-12 weeks. Clinical trials measured results over 72 weeks, showing sustained benefits when paired with consistent effort.
Tirzepatide makes healthy eating easier by reducing appetite and cravings, but you’ll still need to make conscious food choices. Our Personal Health Coach provides nutrition guidance. Most participants find they eat less without feeling deprived, making dietary changes sustainable.
Tirzepatide is available through Dynamis as an out-of-pocket medication filled by licensed U.S. pharmacies. Insurance coverage varies. Our team discusses costs and payment options during your kickoff call. All prescriptions require a comprehensive health assessment first.
